The FDA officially removed semaglutide from the drug-shortage list in February 2025, which narrowed the legal basis for routine 503A compounding of exact-copy semaglutide
Tailored Solutions for GLP-1 RA Research for GLP-1 RA Research Whether you're studying weight loss efficacy, glycemic control, cardiovascular outcomes, or quality of life improvements, Signant Health's ePRO solutions deliver: Robust data collection for primary and secondary endpoints Expert input from our team of 50+ clinicians and COA scientists to drive highest quality evidence generation Evidence generation to support for health technology assessments and economic evaluations 24/7 global patient and site support Seamless integration of decentralized trial elements, such as eConsent, TeleVisits, and more
Restaurant and bar spending decreased from $183 to $127 per month, representing a 31% reduction
The findings revealed a crucial insight, for some GLP-1 s like Saxenda and Wegovy, the high cost of ongoing use surpasses the cost of RYGB in less than a year and sleeve gastrectomy within nine months